Comparison of novel antagonist protocol vs agonist protocol on IVF outcome in poor response patients

Comparison of novel Delayed start antagonist protocol vs Flare up agonist protocol on IVF outcome in poor response patients according to Bologna criteria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091722903N2

Enrollment

Registered

2016-10-03

Start date

2016-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility

Interventions

Intervention 1: Control (Agonist) Group: Basal day 3 hormonal evaluation for FSH, LH, and E2 was done in a natural cycle. Patients will receive a low dose oral contraceptive pill started on cycle day

Eligibility

Sex/Gender

Female

Age

18 Years to 44 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: poor response patients according to Bologna criteria; age between 18-44 years old; BMI: 18-30; access to motile sperm; without any clomifene citrate treatment from 1 month ago; normal menstruation cycles; normal serum prolactin; normal uterine cavity in histrosalpingography. Exclusion criteria: age older than 44 years and Less than 18 years old; history of the hypothalamus or pituitary tumor; history of endocrine diseases such as diabetes, thyroid disorders or adrenal diseases; endometriosis Grade 3 and 4.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Number of oocyte. Timepoint: After intervention. Method of measurement: Microscope.;Oocyte quality. Timepoint: After intervention. Method of measurement: Microscope.;Number of embryo. Timepoint: After intervention. Method of measurement: Microscope.;Embryo quality. Timepoint: After intervention. Method of measurement: Microscope.;Number of cancelled cycles. Timepoint: After intervention. Method of measurement: Patient file.;Number of fertilized oocyte. Timepoint: After intervention. Method of measurement: Microscope.;Expression rate of genes involved in the development of oocyte. Timepoint: After intervention. Method of measurement: Real Time PCR.;Stimulation duration. Timepoint: After intervention. Method of measurement: Patient file.	—

Measure

Time frame

Number of oocyte. Timepoint: After intervention. Method of measurement: Microscope.;Oocyte quality. Timepoint: After intervention. Method of measurement: Microscope.;Number of embryo. Timepoint: After intervention. Method of measurement: Microscope.;Embryo quality. Timepoint: After intervention. Method of measurement: Microscope.;Number of cancelled cycles. Timepoint: After intervention. Method of measurement: Patient file.;Number of fertilized oocyte. Timepoint: After intervention. Method of measurement: Microscope.;Expression rate of genes involved in the development of oocyte. Timepoint: After intervention. Method of measurement: Real Time PCR.;Stimulation duration. Timepoint: After intervention. Method of measurement: Patient file.

—

Secondary

Measure	Time frame
Number of embryo transfer. Timepoint: After intervention. Method of measurement: Patient file.;Number of pregnancy. Timepoint: After intervention. Method of measurement: B-HCG Test.;E2 levels. Timepoint: Before and after intervention. Method of measurement: ELIZA Test.;LH Levels. Timepoint: Before and after intervention. Method of measurement: ELIZA Test.;FSH Levels. Timepoint: Before and after intervention. Method of measurement: ELIZA Test.	—

Measure

Time frame

Number of embryo transfer. Timepoint: After intervention. Method of measurement: Patient file.;Number of pregnancy. Timepoint: After intervention. Method of measurement: B-HCG Test.;E2 levels. Timepoint: Before and after intervention. Method of measurement: ELIZA Test.;LH Levels. Timepoint: Before and after intervention. Method of measurement: ELIZA Test.;FSH Levels. Timepoint: Before and after intervention. Method of measurement: ELIZA Test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Ebrahim Parsanezhad

Shiraz University of Medical Sciences

parsame@sums.ac.irparsanezhad@msn.com+98 71 3212 5419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026